Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Dasatinib with Ketoconazole in CML
NCT05638763Phase 2Unknown
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Start
- Nov 2024
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Primary endpoint: Complete Cytogenetic Response at 6 months. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05638763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638763.